Prometheus Laboratories is a specialized clinical laboratory focused on precision-guided care for Inflammatory Bowel Disease (IBD) and other gastrointestinal (GI) disorders. The company operates in the healthcare diagnostics market, providing a suite of advanced GI diagnostic tests that deliver actionable results throughout a patient's treatment journey. From initial diagnosis to ongoing treatment and monitoring, Prometheus' tests are designed to help healthcare providers make informed decisions to optimize patient care and treatment outcomes.

Prometheus serves a range of clients, primarily healthcare providers such as gastroenterologists and clinics that treat patients with IBD and other GI disorders. The company's diagnostic portfolio includes tests for monitoring thiopurine metabolites, serum drug and antibody levels for medications like infliximab and vedolizumab, and mucosal healing in IBD patients. These tests are validated by extensive clinical research and peer-reviewed publications, ensuring their reliability and accuracy.

The business model of Prometheus Laboratories revolves around providing high-complexity clinical laboratory testing services. The company generates revenue by performing over 1 million tests annually, which are reimbursed by healthcare payers, including insurance companies and government programs. Prometheus is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), which underscores its commitment to maintaining high standards in laboratory testing.

In summary, Prometheus Laboratories is dedicated to enhancing patient care in the GI space through its innovative diagnostic solutions, serving healthcare providers with reliable and actionable test results.

Keywords: GI diagnostics, IBD care, precision medicine, clinical laboratory, thiopurine monitoring, infliximab testing, vedolizumab monitoring, mucosal healing, healthcare providers, patient outcomes.